Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Buy
53
CMRX Quote, Financials, Valuation and Earnings
Last price:
$8.51
Seasonality move
:
4.07%
Day range:
$8.49 - $8.52
52-week range:
$0.75 - $8.52
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.63x
Volume:
3.2M
Avg. volume:
6.6M
1-year change:
789.12%
Market cap:
$764.5M
Revenue:
$324K
EPS (TTM):
-$0.95
Analysts' Opinion
-
Consensus RatingChimerix has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.54, Chimerix has an estimated upside of 0.47% from its current price of $8.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.50 representing -- downside risk from its current price of $8.50.
Fair Value
-
According to the consensus of 4 analysts, Chimerix has 0.47% upside to fair value with a price target of $8.54 per share.
CMRX vs. S&P 500
-
Over the past 5 trading days, Chimerix has underperformed the S&P 500 by -0.04% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Chimerix does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Chimerix has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Chimerix reported revenues of $26K.
Earnings Growth
-
Chimerix has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Chimerix reported earnings per share of -$0.26.
Enterprise value:
628.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.92x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-43.12%
Net Income Margin (TTM):
--
Return On Equity:
-48.22%
Return On Invested Capital:
-48.21%
Operating Margin:
-95357.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $33.1M | $1.1M | -- | $11K | $26K | |
| Gross Profit | $32.6M | -- | -- | -- | -- | |
| Operating Income | -$76.1M | -$96.1M | -$92.8M | -$26.7M | -$24.8M | |
| EBITDA | -$76M | -$96M | -$92.7M | -$26.7M | -$24.8M | |
| Diluted EPS | $1.75 | -$0.96 | -$0.95 | -$0.27 | -$0.26 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $90.2M | $128.5M | $291.1M | $200.6M | $140.9M | |
| Total Assets | $93.5M | $133.4M | $293.9M | $225.3M | $158.7M | |
| Current Liabilities | $7.4M | $26.3M | $17.7M | $15.5M | $22.2M | |
| Total Liabilities | $10.3M | $28.8M | $19.9M | $17M | $22.9M | |
| Total Equity | $83.2M | $104.6M | $274M | $208.3M | $135.8M | |
| Total Debt | -- | $14M | $250K | $125K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$60.9M | -$74.5M | -$70.3M | -$17.9M | -$20.5M | |
| Cash From Investing | $321.6M | -$185.9M | $79.4M | $11.9M | $28.3M | |
| Cash From Financing | -$12.6M | $214K | $406K | $78K | $178K | |
| Free Cash Flow | -$61M | -$74.6M | -$70.4M | -$17.9M | -$20.5M | |
CMRX
Sector
Market Cap
$764.5M
$39.2M
Price % of 52-Week High
99.77%
45.99%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
789.12%
-38.63%
Beta (5-Year)
0.324
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$8.47
200-day SMA
Buy
Level
$2.16
Bollinger Bands (100)
Buy
Level
1.09 - 5.77
Chaikin Money Flow
Sell
Level
-2.7M
20-day SMA
Buy
Level
$7.06
Relative Strength Index (RSI14)
Buy
Level
84.25
ADX Line
Buy
Level
13.78
Williams %R
Sell
Level
-0.5464
50-day SMA
Buy
Level
$5.20
MACD (12, 26)
Buy
Level
1.20
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
1.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.1127)
Buy
CA Score
(Annual)
Level (-0.2688)
Buy
Beneish M-Score
(Annual)
Level (-24.0611)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.4853)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Stock Forecast FAQ
In the current month, CMRX has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The CMRX average analyst price target in the past 3 months is $8.54.
-
Where Will Chimerix Stock Be In 1 Year?
According to analysts, the consensus estimate is that Chimerix share price will rise to $8.54 per share over the next 12 months.
-
What Do Analysts Say About Chimerix?
Analysts are divided on their view about Chimerix share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Chimerix is a Sell and believe this share price will drop from its current level to $8.50.
-
What Is Chimerix's Price Target?
The price target for Chimerix over the next 1-year time period is forecast to be $8.54 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is CMRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Chimerix is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CMRX?
You can purchase shares of Chimerix via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Chimerix shares.
-
What Is The Chimerix Share Price Today?
Chimerix was last trading at $8.51 per share. This represents the most recent stock quote for Chimerix. Yesterday, Chimerix closed at $8.50 per share.
-
How To Buy Chimerix Stock Online?
In order to purchase Chimerix stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is CyberArk Stock a Buy, Sell or Hold?
CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has…
Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 20
Regencell Bioscience Holdings [RGC] is down 0% over the past day.
Sell
36
VMI alert for Mar 20
Valmont Industries [VMI] is down 0% over the past day.
Buy
61
ALNY alert for Mar 20
Alnylam Pharmaceuticals [ALNY] is down 0% over the past day.
